European Journal of Epidemiology

, Volume 25, Issue 2, pp 143–148 | Cite as

Incidence and risk for acute hepatitis C infection during imprisonment in Australia

  • Kate Dolan
  • Suzy Teutsch
  • Nicolas Scheuer
  • Michael Levy
  • William Rawlinson
  • John Kaldor
  • Andrew Lloyd
  • Paul Haber
Infectious Diseases

Abstract

To determine hepatitis C incidence and the demographic and behavioural predictors in seronegative drug injecting prisoners. Prisoners in New South Wales, Australia who: were aged 18 years and over; reported IDU; had been continuously imprisoned; had a documented negative HCV antibody test result in prison in the last 12 months; provided written informed consent. Subjects were interviewed about their demographic characteristics and detailed risk factors for transmission prior to, and since, imprisonment. A blood sample was collected to screen for HCV antibodies by ELISA and RNA by PCR. Of 253 inmates recruited, 120 were continuously imprisoned and included in this analysis. Sixteen acquired HCV infection indicating an incidence of 34.2 per 100 person years (CI: 19.6–55.6). Risk factors for transmission included prior imprisonment, methadone treatment and greater than 10 years of education. Although the frequency of injecting was reduced in prison, 33.6% continued to inject drugs, most commonly methamphetamine, and 90% of these reported sharing injecting equipment. Prison inmates were at high risk of HCV infection, despite some reduction in high-risk behaviours and access to prevention services. To prevent HCV transmission in prisons, better prevention strategies are required.

Keywords

Prisoners Hepatitis C Injecting drug use Incidence 

Abbreviations

HCV

Hepatitis C virus

IDU

Injecting drug use(rs)

NSW

New South Wales

References

  1. 1.
    Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558–67.CrossRefPubMedGoogle Scholar
  2. 2.
    Jurgens R, Ball A, Verster A. Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis. 2009;9:57–66.CrossRefPubMedGoogle Scholar
  3. 3.
    Correctional Service Canada. 1995 National inmate survey: Final report [No. SR-02]. Ottawa: Correctional Service Canada; 1996.Google Scholar
  4. 4.
    Gore SM, Bird AG, Burns SM, Goldberg DJ, Ross AJ, Macgregor J. Drug injection and HIV prevalence in inmates of Glenochil prison. Brit Med J. 1995;310(6975):293–6.PubMedGoogle Scholar
  5. 5.
    O’Sullivan BG, Levy MH, Dolan KA, Post JJ, Barton SG, Dwyer DE, et al. Hepatitis C transmission and HIV post-exposure prophylaxis after needle- and syringe-sharing in Australian prisons. Med J Aust. 2003;178(11):546–9.PubMedGoogle Scholar
  6. 6.
    Post JJ, Dolan KA, Whybin LR, Carter IW, Haber PS, Lloyd AR. Acute hepatitis C virus infection in an Australian prison inmate: tattooing as a possible transmission route. Med J Aust. 2001;174(4):183–4.PubMedGoogle Scholar
  7. 7.
    Rosen HR. Acquisition of hepatitis C by a conjunctival splash. Am J Infect Control. 1997;25:242–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Haber PS, Parsons SJ, Harper SE, White PA, Rawlinson WD, Lloyd AR. Transmission of hepatitis C within Australian prisons. Med J Aust. 1999;171(1):31–4.PubMedGoogle Scholar
  9. 9.
    Neaigus A, Gyarmathy VA, Zhao M, Miller M, Friedman SR, Des Jarlais DC. Sexual and other noninjection risks for HBV and HCV seroconversions among non-injecting heroin users. J Infect Dis. 2007;195(7):1052–61.CrossRefPubMedGoogle Scholar
  10. 10.
    Macalino GE, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health. 2004;94(7):1218–23.CrossRefPubMedGoogle Scholar
  11. 11.
    Vlahov D, Nelson KE, Quinn TC, Kendig N. Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland. Eur J Epidemiol. 1993;9(5):566–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Arrada A, Zak Dit Zbar O, Vasseur V. Prevalence of HBV and HCV infections and incidence of HCV infection after 3, 6 and 12 months detention in La Sante prison, Paris. Ann Med Interne (Paris). 2001;152(Suppl 7):6–8.Google Scholar
  13. 13.
    Crofts N, Stewart T, Hearne P, Ping XY, Breshkin AM, Locarnini SA. Spread of bloodborne viruses among Australian prison entrants. Brit Med J. 1995;310(6975):285–8.PubMedGoogle Scholar
  14. 14.
    Christensen PB, Krarup HB, Niesters HG, Norder H, Georgsen J. Prevalence and incidence of bloodborne viral infections among Danish prisoners. Eur J Epidemiol. 2000;16(11):1043–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Dolan KA, Shearer J, White B, Zhou J, Wodak A. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, reincarceration and hepatitis C infection. Addiction. 2005;100(6):820–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behaviour and criminality: a meta-analysis. Addiction. 1998;93:515–32.CrossRefPubMedGoogle Scholar
  17. 17.
    Gowing L, Farrell M, Bornemann R, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2004;4:CD0041453.Google Scholar
  18. 18.
    Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend. 2003;72(1):59–65.CrossRefPubMedGoogle Scholar
  19. 19.
    Barnett PG, Hui SS. The cost-effectiveness of methadone maintenance. Mt Sinai J Med. 2000;67:365–74.PubMedGoogle Scholar
  20. 20.
    Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28:321–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Dolan K, Wodak A. An international review of methadone provision in prisons. Addict Res. 1996;4(1):85–97.CrossRefGoogle Scholar
  22. 22.
    Larney S, Dolan K. A literature review of international implementation of opioid substitution treatment in prisons: equivalence of care? Euro Addict Res. 2009;15:107–12.CrossRefGoogle Scholar
  23. 23.
    Clayton D, Hills M. Statistical models in epidemiology. Oxford: Oxford University Press; 1993.Google Scholar
  24. 24.
    Goldberg D, Taylor A. Preventing transmission of bloodborne virus infections in prisons. Commun Dis Public Health. 2000;3(2):84–5.PubMedGoogle Scholar
  25. 25.
    Power KG, Markova I, Rowlands A, McKee KJ, Anslow PJ, Kilfedder C. Intravenous drug use and HIV transmission amongst inmates in Scottish prisons. Br J Addict. 1992;87(1):35–45.CrossRefPubMedGoogle Scholar
  26. 26.
    Hallinan R, Byrne A, Amin J, Dore G. Hepatitis C virus prevalence and outcomes among IDUs on opioid replacement therapy. J Gastroenterol Hepatol. 2005;20:1082–6.PubMedGoogle Scholar
  27. 27.
    Dolan K, Hall W, Wodak A. Methadone maintenance reduces injecting in prison. Brit Med J. 1996;312:1162.PubMedGoogle Scholar
  28. 28.
    New South Wales Opioid Treatment Program. Clinical guidelines for methadone and buprenorphine treatment of opioid dependence. New South Wales Health. 2006. Available at www.nsw.health.gov.au.
  29. 29.
    Australian Bureau of Statistics, Prisoners in Australia. 2008. http://www.abs.gov.au/ausstats/abs@.nsf/cat/4517.0 accessed 8 Dec 2009).
  30. 30.
    National Centre in HIV Epidemiology and Clinical Research. Return on Investment 2: Evaluating the cost-effectiveness of needle and syringe programs in Australia, 2009. Sydney. 2009.Google Scholar
  31. 31.
    Dolan K, Larney S, Jacka B, Rawlinson W. Presence of hepatitis C virus in syringes confiscated in prisons in Australia. J Gastroenterol Hepatol. 2009;24(10):1655–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Dolan K, Hall W, Wodak A, Gaughwin M. Evidence of HIV transmission in an Australian prison. Letter Med J Aust. 1994;160:734.Google Scholar
  33. 33.
    Larney S, Dolan K. Increased access to opioid substitution treatment in prisons is needed to ensure equivalence of care. Aust NZ J Pub Health. 2008;32:86–7.CrossRefGoogle Scholar
  34. 34.
    Dolan K, Kite B, Black E, Aceijas C, Stimson GV. HIV in prison in low-income and middle-income countries. Lancet Infect Dis. 2007;7:32–41.CrossRefPubMedGoogle Scholar
  35. 35.
    Barroon LH. Subjects or objects? Prisoners and human experimentation. New England J Med. 2007;356:1806–7.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Kate Dolan
    • 1
  • Suzy Teutsch
    • 2
  • Nicolas Scheuer
    • 1
  • Michael Levy
    • 3
  • William Rawlinson
    • 4
  • John Kaldor
    • 5
  • Andrew Lloyd
    • 2
  • Paul Haber
    • 6
  1. 1.National Drug and Alcohol Research CentreUniversity of New South WalesSydneyAustralia
  2. 2.Centre for Infection and Inflammation Research, School of Medical SciencesUniversity of New South WalesSydneyAustralia
  3. 3.School of Public HealthThe University of SydneySydneyAustralia
  4. 4.Virology DivisionSEALS, Prince of Wales HospitalRandwickAustralia
  5. 5.National Centre for HIV Epidemiology and Clinical ResearchUniversity of New South WalesSydneyAustralia
  6. 6.Drug Health Services, Royal Prince Alfred Hospital and Discipline of Addiction MedicineUniversity of SydneySydneyAustralia

Personalised recommendations